SHAREHOLDER DEADLINE: Regeneron Pharmaceuticals (REGN) Investors Are Reminded of Deadline in Securities Action
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...
FiercePharma1d
Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Regeneron Pharmaceuticals REGN +0.75% Get Free Report has outperformed the market over the past 20 years by 17.78% on an annualized basis producing an average annual return of 26.11%. Currently, ...
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
The stock's fall snapped a three-day winning streak.
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,000.00 Price Target at Bernstein Bank
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price lowered by equities researchers at Bernstein Bank from $1,070.00 to $1,000.00 in a research note issued to investors on ...
FiercePharma3d
Regeneron's Libtayo reaches blockbuster status and has potential for more growth: execs
As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.
Seeking Alpha3d
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript
Such statements may include, but are not limited to those related to Regeneron and its products and business, financial forecast and guidance, development programs and related anticipated ...
Nasdaq3d
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ ... but it is a good mix of established and up-and-coming products, plus it's doing well with collaborations ...
Insider Monkey3d
Is Regeneron Pharmaceuticals (REGN) the Best Cancer Stock to Buy According to Hedge Funds?
It has relied on two primary products to drive top-line growth in the past years: Dupixent and Eylea. Dupixent is an eczema treatment whose rights Regeneron Pharmaceuticals, Inc. (NASDAQ ...
Nasdaq3d
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...
RBC cuts Regeneron stock price target to $1,045, keeps Outperform
RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm maintained its ...